Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.43 |
| ▸ | EED | O75530 | 1/20 | 0.41 |
| ▸ | REN | P00797 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096911 | 1.00 | SLC6A4 (0.43) | SLC6A4EEDRENHTR2CHTR2B | |
| SCHEMBL6098050 | 0.87 | MDM2 (0.37) | SLC6A4HTR2CHTR2BTACR1SLC6A2 | |
| SCHEMBL6097113 | 0.87 | MDM2 (0.37) | SLC6A4HTR2CHTR2BTACR1SLC6A2 | |
| SCHEMBL6097050 | 0.87 | SLC6A4 (0.38) | SLC6A4RENHTR2CHTR2BTACR1 | |
| SCHEMBL6097047 | 0.87 | SLC6A4 (0.38) | SLC6A4RENHTR2CHTR2BTACR1 | |
| SCHEMBL6094572 | 0.87 | SLC6A4 (0.38) | SLC6A4RENHTR2CHTR2BTACR1 | |
| SCHEMBL6271985 | 0.87 | MDM2 (0.37) | SLC6A4HTR2CHTR2BTACR1SLC6A2 | |
| SCHEMBL6098052 | 0.87 | MDM2 (0.37) | SLC6A4HTR2CHTR2BTACR1SLC6A2 | |
| SCHEMBL6096075 | 0.85 | SLC6A2 (0.40) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6094493 | 0.85 | SLC6A2 (0.40) | SLC6A4SLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1605941-A1 | SUBSTITUTED PIPERIDINES AS NOVEL MDM2-p53 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | claimed |
| US-6916833-B2 | Substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | claimed |
| WO-2004080460-A1 | SUBSTITUTED PIPERIDINES AS NOVEL MDM2-p53 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | claimed |
| US-20040180929-A1 | Nitrogen compounds such as 4-Benzyloxy-4-(4-chlorophenyl)-3-(3,4-difluorobenzyloxy)-piperidine, administered as oncoprotein or ubiquitin-conjugating enzyme antagonists for prophylaxis of cancer; anticarcinogenic agents | KIM KYUNGJIN (US) | 2004-09-16 | — | — | US | claimed |
| US-7060713-B2 | Substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1605941-A1 | SUBSTITUTED PIPERIDINES AS NOVEL MDM2-p53 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-21 | — | — | EP | disclosed |
| US-20050171157-A1 | 3-alkyl- or alkenyloxy-4-phenyl-4-phenylalkoxypiperidines that may be N-substituted, e.g., cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-butyloxy-piperidine; treating breast or colon cancer | KIM KYUNGJIN (US) | 2005-08-04 | — | — | US | disclosed |
| US-6916833-B2 | Substituted piperidines | HOFFMANN-LA ROCHE INC. (US) | 2005-07-12 | — | — | US | disclosed |
| WO-2004080460-A1 | SUBSTITUTED PIPERIDINES AS NOVEL MDM2-p53 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-09-23 | — | — | WO | disclosed |
| US-20040180929-A1 | Nitrogen compounds such as 4-Benzyloxy-4-(4-chlorophenyl)-3-(3,4-difluorobenzyloxy)-piperidine, administered as oncoprotein or ubiquitin-conjugating enzyme antagonists for prophylaxis of cancer; anticarcinogenic agents | KIM KYUNGJIN (US) | 2004-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171157-A1 | 3-alkyl- or alkenyloxy-4-phenyl-4-phenylalkoxypiperidines that may be N-substituted, e.g., cis-[rac]-4-Benzyloxy-4-(4-fluoro-phenyl)-3-butyloxy-piperidine; treating breast or colon cancer | KRAS, TMEM205, ABCB11 | SLC6A4 425/4885EED 2437/4885REN 897/4885 |
| US-20040180929-A1 | Nitrogen compounds such as 4-Benzyloxy-4-(4-chlorophenyl)-3-(3,4-difluorobenzyloxy)-piperidine, administered as oncoprotein or ubiquitin-conjugating enzyme antagonists for prophylaxis of cancer; anticarcinogenic agents | PSMB1, UBQLN1, UBE2N | SLC6A4 4038/4885EED 1728/4885REN 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.